TrialNature medicine2021

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.

Tina Cascone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.